{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T23:32:15Z","timestamp":1777851135421,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Geriatr Psychiatry Neurol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Agitation is common in persons living with dementia (major neurocognitive disorder) and worsens with disease progression. Brexpiprazole is the sole FDA-approved drug for agitation in persons with Alzheimer\u2019s dementia, but requires daily dosing over weeks. Limited pharmacologic options exist for acute agitation management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To show the efficacy of oxytocin for acute agitation management in dementia patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>We report a 70-year-old former professional wrestler with repetitive head trauma who developed dementia and severe agitation. He showed remarkable, rapid improvement with as-needed intranasal oxytocin 30 IU until his death. Post-mortem examination revealed mixed pathology: Alzheimer\u2019s disease (Intermediate stage), Lewy Body disease (Limbic\/Transitional stage), cerebrovascular disease with multiple infarcts, and chronic traumatic encephalopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates the potential efficacy of intranasal oxytocin for acute agitation management in persons living with mixed dementia and may inspire further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08919887251382495","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T23:19:38Z","timestamp":1758323978000},"page":"426-430","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intranasal Oxytocin for Managing Agitation in a Patient of Mixed Dementia With Multiple Pathologies, Particularly With a History of Repetitive Head Injuries"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4337-5533","authenticated-orcid":false,"given":"Naresh","family":"Jadav","sequence":"first","affiliation":[{"name":"Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00fcmeyye","family":"Ku\u015f","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Ellison","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Weisman","sequence":"additional","affiliation":[{"name":"Abington Neurological Associates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-2892","authenticated-orcid":false,"given":"Mijail D.","family":"Serruya","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116662"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a55f7f"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2011.01186.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00445"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.8334"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000686"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2004.09.031"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4037"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000067972"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796016001098"},{"key":"e_1_3_3_13_2","unstructured":"FDA News Release. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease. Published: May 11 2023. Last accessed: Feb 20 2024."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158668"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr171"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00456-3"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0427-2"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01845-8"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-190372"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.12.007"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001133"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr171"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316681839"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015154"}],"container-title":["Journal of Geriatric Psychiatry and Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887251382495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08919887251382495","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887251382495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:17:13Z","timestamp":1777501033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08919887251382495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/08919887251382495"],"URL":"https:\/\/doi.org\/10.1177\/08919887251382495","relation":{},"ISSN":["0891-9887","1552-5708"],"issn-type":[{"value":"0891-9887","type":"print"},{"value":"1552-5708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}